[Diagnostics and treatment of statin-associated muscle symptoms].
Diagnostik und Therapie von statinassoziierten Muskelsymptomen.
Creatine kinase
Genetic predisposition to disease
HMG CoA reductase
Myalgia
Myopathies
Journal
Der Internist
ISSN: 1432-1289
Titre abrégé: Internist (Berl)
Pays: Germany
ID NLM: 0264620
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
04
05
2021
pubmed:
19
6
2021
medline:
28
7
2021
entrez:
18
6
2021
Statut:
ppublish
Résumé
Statins are among the most frequently prescribed drugs in Germany. Their benefits in lowering cardiovascular risk are beyond dispute. Nevertheless, many patients complain of side effects from statin therapy, including statin-associated muscle symptoms (SAMS) in particular. Despite their relative frequency, it is difficult to objectively diagnose them, as the time until appearance of first symptoms, the nature of the complaints and the severity of muscle problems vary widely. This narrative review summarizes the causes of SAMS as well as new possibilities regarding their diagnosis and therapy. Statine zählen zu den am häufigsten verordneten Medikamenten deutschlandweit. Ihr Nutzen in der Senkung des kardiovaskulären Risikos ist unbestritten. Dennoch klagen viele Patienten über Nebenwirkungen unter Statintherapie, wozu insbesondere statinassoziierte Muskelsymptome (SAMS) zählen. Diese sind trotz ihrer relativen Häufigkeit schwer zu erfassen und objektiv zu diagnostizieren, da der Zeitraum bis zum ersten Auftreten von Symptomen, die Art der Beschwerden und der Schweregrad der Muskelprobleme sehr stark variieren. In diesem narrativen Review werden die Ursachen der SAMS sowie neue Möglichkeiten zur Diagnostik und Therapie zusammengefasst.
Autres résumés
Type: Publisher
(ger)
Statine zählen zu den am häufigsten verordneten Medikamenten deutschlandweit. Ihr Nutzen in der Senkung des kardiovaskulären Risikos ist unbestritten. Dennoch klagen viele Patienten über Nebenwirkungen unter Statintherapie, wozu insbesondere statinassoziierte Muskelsymptome (SAMS) zählen. Diese sind trotz ihrer relativen Häufigkeit schwer zu erfassen und objektiv zu diagnostizieren, da der Zeitraum bis zum ersten Auftreten von Symptomen, die Art der Beschwerden und der Schweregrad der Muskelprobleme sehr stark variieren. In diesem narrativen Review werden die Ursachen der SAMS sowie neue Möglichkeiten zur Diagnostik und Therapie zusammengefasst.
Identifiants
pubmed: 34143250
doi: 10.1007/s00108-021-01059-0
pii: 10.1007/s00108-021-01059-0
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
827-840Informations de copyright
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517–526
pubmed: 12815379
doi: 10.1038/nrd1112
pmcid: 12815379
WHO (Hrsg) (2016) Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000–2016. World Health Organization, Geneva
Laufs U, Scharnagl H, Halle M, Windler E, Endres M, März W (2015) Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Arztebl Int 112:748–755
pubmed: 26575138
pmcid: 4650909
Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W (2018) Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: the CaReHigh Registry. Atherosclerosis 277:314–322
pubmed: 30270065
doi: 10.1016/j.atherosclerosis.2018.08.050
pmcid: 30270065
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M‑R, Tokgozoglu L, Wiklund O, Mueller C, Drexel H, Aboyans V, Corsini A, Doehner W, Farnier M, Gigante B, Kayikcioglu M, Krstacic G, Lambrinou E, Lewis BS, Masip J, Moulin P, Petersen S, Petronio AS, Piepoli MF, Pintó X, Räber L, Ray KK, Reiner Ž, Riesen WF, Roffi M, Schmid J‑P, Shlyakhto E, Simpson IA, Stroes E, Sudano I, Tselepis AD, Viigimaa M, Vindis C, Vonbank A, Vrablik M, Vrsalovic M, Zamorano JL, Collet J‑P, Koskinas KC, Casula M, Badimon L, John Chapman M, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M‑R, Tokgozoglu L, Wiklund O, Windecker S, Aboyans V, Baigent C, Collet J‑P, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafov R, Van De Borne P, Pojskic B, Postadzhiyan A, Kypris L, Špinar J, Larsen ML, Eldin HS, Viigimaa M, Strandberg TE, Ferrières J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudjónsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, Visser L, Dingli P, Ivanov V, Boskovic A, Nazzi M, Visseren F, Mitevska I, Retterstøl K, Jankowski P, Fontes-Carvalho R, Gaita D, Ezhov M, Foscoli M, Giga V, Pella D, Fras Z, De Isla LP, Hagström E, Lehmann R, Abid L, Ozdogan O, Mitchenko O, Patel RS: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020;41:111–188
Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang F‑T, Poh KK, Brudi P, Ambegaonkar B (2017) Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II. Atherosclerosis 266:158–166
pubmed: 29028484
doi: 10.1016/j.atherosclerosis.2017.08.013
pmcid: 29028484
Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP (2020) N‑of‑1 trial of a Statin, placebo, or no treatment to assess side effects. N Engl J Med 383:2182–2184. https://doi.org/10.1056/NEJMc2031173
doi: 10.1056/NEJMc2031173
pubmed: 33196154
pmcid: 33196154
Knoblauch H, Schoewel V, Rosada A, Spuler S, Kress W (2010) Another side to Statin-related side effects. Ann Intern Med 152:478–479
pubmed: 20368665
doi: 10.7326/0003-4819-152-7-201004060-00025
pmcid: 20368665
Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD (2013) Effect of Statins on skeletal muscle function. Circulation 127:96–103
pubmed: 23183941
doi: 10.1161/CIRCULATIONAHA.112.136101
pmcid: 23183941
Graham DJ (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585
doi: 10.1001/jama.292.21.2585
Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M (2017) Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 22:85–96
pubmed: 27634340
doi: 10.1016/j.drudis.2016.09.001
pmcid: 27634340
Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS (2018) Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res 114:1073–1081
pubmed: 29878063
pmcid: 6014181
doi: 10.1093/cvr/cvy119
Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC (2011) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136
pubmed: 21992719
pmcid: 3204270
doi: 10.1186/1471-2350-12-136
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54:1609–1616
pubmed: 19833260
pmcid: 3417133
doi: 10.1016/j.jacc.2009.04.053
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH (2010) Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 19:75–81
pubmed: 19802823
doi: 10.1002/pds.1866
pmcid: 19802823
Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11:274–286
pubmed: 20386561
doi: 10.1038/tpj.2010.28
pmcid: 20386561
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2004) CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 93:104–107
pubmed: 14697480
doi: 10.1016/j.amjcard.2003.08.078
pmcid: 14697480
Ruaño G, Thompson PD, Windemuth A, Seip RL, Dande A, Sorokin A, Kocherla M, Smith A, Holford TR, Wu AH (2007) Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36:329–335
pubmed: 17600820
doi: 10.1002/mus.20871
pmcid: 17600820
www.snpedia.com . Zugegriffen: 22.10.2020
Ovesjö M‑L, Skilving I, Bergman P, Rane A, Ekström L, Björkhem-Bergman L (2016) Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of Statin-induced myopathy. Basic Clin Pharmacol Toxicol 118:214–218
pubmed: 26423691
pmcid: 26423691
doi: 10.1111/bcpt.12482
Gupta A, Thompson PD (2011) The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 215:23–29
pubmed: 21185021
pmcid: 21185021
doi: 10.1016/j.atherosclerosis.2010.11.039
Mammen AL (2016) Statin-associated autoimmune myopathy. N Engl J Med 374:664–669
pubmed: 26886523
doi: 10.1056/NEJMra1515161
pmcid: 26886523
Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Watts GF, Blumenthal RS, Lip GY, Mikhailidis DP, Sahebkar A: (2015) Statin therapy and plasma coenzyme Q10 concentrations-—a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 99:329–336
pubmed: 26192349
doi: 10.1016/j.phrs.2015.07.008
pmcid: 26192349
Paiva H, Thelen K, Coster R, Smet J, Paepe B, Mattila K, Laakso J, Lehtimaki T, Vonbergmann K, Lutjohann D (2005) High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78(1):60–68. https://doi.org/10.1016/j.clpt.2005.03.006
doi: 10.1016/j.clpt.2005.03.006
pubmed: 16003294
pmcid: 16003294
Hanai J‑I, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH (2007) The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
doi: 10.1172/JCI32741
Abd TT, Jacobson TA (2011) Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10:373–387
pubmed: 21342078
doi: 10.1517/14740338.2011.540568
pmcid: 21342078
Wang C‑Y, Liu P‑Y, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37–44
pubmed: 18068482
pmcid: 2621332
doi: 10.1016/j.molmed.2007.11.004
Grunwald SA, Popp O, Haafke S, Jedraszczak N, Grieben U, Saar K, Patone G, Kress W, Steinhagen-Thiessen E, Dittmar G, Spuler S (2020) Statin-induced myopathic changes in primary human muscle cells and reversal by a prostaglandin F2 alpha analogue. Sci Rep 10:2158
pubmed: 32034223
pmcid: 7005895
doi: 10.1038/s41598-020-58668-2
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA (2014) An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8:S58–S71
pubmed: 24793443
doi: 10.1016/j.jacl.2014.03.004
pmcid: 24793443
(2020) Clinical drug interaction studies—Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions . Zugegriffen: article online
Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, Gomes T, Fleet J, Hwang YJ, Garg AX (2013) Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med 158:869–876
pubmed: 23778904
doi: 10.7326/0003-4819-158-12-201306180-00004
pmcid: 23778904
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, Stroes E, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, Krauss RM, Laufs U, Santos RD, März W, Newman CB, Chapman JM, Ginsberg HN, Chapman JM, Ginsberg HN, De Backer G, Catapano AL, Hegele RA, Kees Hovingh G, Jacobson TA, Leiter L, Mach F, Wiklund O (2015) Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36:1012–1022
pubmed: 25694464
pmcid: 4416140
doi: 10.1093/eurheartj/ehv043
Taylor BA, Sanchez RJ, Jacobson TA, Chibedi-De-Roche D, Manvelian G, Baccara-Dinet MT, Khan I, Rosenson RS (2017) Application of the Statin-associated muscle symptoms-clinical index to a randomized trial on Statin Myopathy. J Am Coll Cardiol 70:1680–1681
pubmed: 28935043
doi: 10.1016/j.jacc.2017.07.767
pmcid: 28935043
Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A (2008) Are statin medications safe in patients with ALS? Amyotroph Lateral Scler 9:223–228
pubmed: 18608105
doi: 10.1080/17482960802031092
pmcid: 18608105
Al-Jubouri MA, Briston PG, Sinclair D, Chinn RH, Young RM (1994) Lesson of the week: myxoedema revealed by simvastatin induced myopathy. BMJ 308:588–588
pubmed: 8148686
pmcid: 2539565
doi: 10.1136/bmj.308.6928.588
Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ (2015) Statin intolerance because of Myalgia, Myositis, Myopathy, or Myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci 7:86–93
pubmed: 25838999
pmcid: 25838999
doi: 10.4103/1947-2714.153919
Haynes R, Jiang L, Hopewell JC, Li J, Chen F, Parish S, Landray MJ, Collins R, Armitage J, Collins R, Armitage J, Baigent C, Chen Z, Landray M, Chen Y, Jiang L, Pedersen T, Landray M, Bowman L, Chen F, Hill M, Haynes R, Knott C, Rahimi K, Tobert J, Sleight P, Simpson D, Parish S, Baxter A, Lay M, Bray C, Wincott E, Leijenhorst G, Skattebol A, Moen G, Mitchel Y, Kuznetsova O, Macmahon S, Kjekshus J, Hill C, Lam TH, Sandercock P, Peto R, Hopewell JC (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34:1279–1291
pmcid: 3640201
doi: 10.1093/eurheartj/eht055
Neal RC, Ferdinand KC, Ycas J, Miller E (2009) Relationship of ethnic origin, gender, and age to blood creatine kinase levels. Am J Med 122:73–78
pubmed: 19114174
pmcid: 19114174
doi: 10.1016/j.amjmed.2008.08.033
Liu C‑Y, Lai Y‑C, Wu Y‑C, Tzeng C‑H, Lee S‑D (2010) Macroenzyme creatine kinase in the era of modern laboratory. Medicine 73:35–39
Newman CB, Tobert JA (2015) Statin intolerance: reconciling clinical trials and clinical experience. JAMA 313:1011–1012
pubmed: 25756433
doi: 10.1001/jama.2015.1335
pmcid: 25756433
Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581–585
pubmed: 12353945
doi: 10.7326/0003-4819-137-7-200210010-00009
pmcid: 12353945
Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P (2017) Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389:2473–2481
pubmed: 28476288
doi: 10.1016/S0140-6736(17)31075-9
pmcid: 28476288
Taylor BA, Thompson PD (2018) Statin-associated muscle disease: advances in diagnosis and management. Neurotherapeutics 15:1006–1017
pubmed: 30251222
pmcid: 30251222
doi: 10.1007/s13311-018-0670-z
Korhonen MJ, Pentti J, Hartikainen J, Kivimäki M, Vahtera J (2016) Somatic symptoms of anxiety and nonadherence to statin therapy. Int J Cardiol 214:493–499
pubmed: 27100341
doi: 10.1016/j.ijcard.2016.04.003
pmcid: 27100341
Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, Taylor B, Khan I, Manvelian G, White M, Jacobson TA (2017) The Statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther 31:179–186
pubmed: 28421332
pmcid: 5427100
doi: 10.1007/s10557-017-6723-4
Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD (2017) Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 70:1290–1301
pubmed: 28859793
doi: 10.1016/j.jacc.2017.07.752
pmcid: 28859793
Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J, Banach M (2017) Efficacy and safety of alternate-day versus daily dosing of Statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther 31:419–431
pubmed: 28741244
doi: 10.1007/s10557-017-6743-0
pmcid: 28741244
Alfaddagh A, Elajami TK, Saleh M, Elajami M, Bistrian BR, Welty FK (2018) The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a randomized clinical trial. J Clin Lipidol 12:937–947.e2
pubmed: 29752179
pmcid: 8037678
doi: 10.1016/j.jacl.2018.03.080
Alfaddagh A, Elajami TK, Ashfaque H, Saleh M, Bistrian BR, Welty FK (2017) Effect of eicosapentaenoic and docosahexaenoic acids added to Statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. J Am Heart Assoc 6:e6981
pubmed: 29246960
pmcid: 5779017
doi: 10.1161/JAHA.117.006981
Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ (2018) Effects of coenzyme Q10 on Statin-induced Myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc 7(19):e009835. https://doi.org/10.1161/JAHA.118.009835
doi: 10.1161/JAHA.118.009835
pubmed: 30371340
pmcid: 6404871
Sudhop T, LüTjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, Von Bergmann K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943–1948
pubmed: 12370217
doi: 10.1161/01.CIR.0000034044.95911.DC
pmcid: 12370217
Rosenson RS, Hegele RA, Fazio S, Cannon CP (2018) The evolving future of PCSK9 inhibitors. J Am Coll Cardiol 72:314–329
pubmed: 30012326
doi: 10.1016/j.jacc.2018.04.054
pmcid: 30012326
(2018) Evolocumab. https://www.g-ba.de/downloads/91-1385-354/2018-09-06_Geltende-Fassung_Evolocumab_D-345.pdf . Zugegriffen: 1. Apr. 2020
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382:1507–1519
pubmed: 32187462
doi: 10.1056/NEJMoa1912387
pmcid: 32187462
(2020) Nilemdo 180 mg Filmtabletten – Zusammenfassung der Merkmale des Arzneimittels. https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_de.pdf . Zugegriffen: 17. Nov. 2020
(2020) Nustendi 180 mg/10 mg Filmtabletten – Zusammenfassung der Merkmale des Arzneimittels. https://ec.europa.eu/health/documents/community-register/2020/20200327147391/anx_147391_de.pdf . Zugegriffen: 17. Nov. 2020
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM (2019) Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 380:1022–1032
pubmed: 30865796
doi: 10.1056/NEJMoa1803917
pmcid: 30865796
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB (2019) Effect of bempedoic acid vs placebo added to maximally tolerated Statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease. JAMA 322:1780
pubmed: 31714986
pmcid: 6865290
doi: 10.1001/jama.2019.16585
Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA (2018) Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 277:195–203
pubmed: 29910030
doi: 10.1016/j.atherosclerosis.2018.06.002
pmcid: 29910030
Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL‑C and attenuates atherosclerosis. Nat Commun 7:13457
pubmed: 27892461
pmcid: 5133702
doi: 10.1038/ncomms13457
Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG (2019) Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and Statin intolerance. J Am Heart Assoc 8(7):e011662. https://doi.org/10.1161/JAHA.118.011662
doi: 10.1161/JAHA.118.011662
pubmed: 30922146
pmcid: 6509724
Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL (2020) Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiolog 27:593–603
doi: 10.1177/2047487319864671
Cicero AFG, Fogacci F, Hernandez AV, Banach M (2020) Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med 17:e1003121
pubmed: 32673317
pmcid: 7365413
doi: 10.1371/journal.pmed.1003121
(2016) Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). NCT02993406. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02993406 . Zugegriffen: 22. Aug. 2020
Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C (2020) Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf 43(8):727–736. https://doi.org/10.1007/s40264-020-00931-6
doi: 10.1007/s40264-020-00931-6
pubmed: 32358698
pmcid: 32358698